Currax Pharmaceuticals to Spotlight New Research at ObesityWeek® 2025 Highlighting Craving Control, Behavioral Adherence, and Subpopulation Outcomes with CONTRAVE®

Data to be shared during an ObesityWeek press conference includes four of seven data presentations supporting CONTRAVE and its utility in helping people lose weight

Brentwood, Tenn., Oct. 28, 2025 — Currax Pharmaceuticals LLC (“Currax”), a platform company that delivers life-changing medicines to patients with chronic, progressive diseases, will present multiple new data sets at ObesityWeek® 2025, the annual meeting of The Obesity Society, held Nov. 4–7 in Atlanta.

Currax will showcase seven data presentations at ObesityWeek, including four selected for the event’s official press conference on Wednesday, Nov. 5, 2025. The data underscore the differentiated profile of CONTRAVE® (naltrexone HCl/bupropion HCl) as an oral, non-GLP-1 combination therapy intended to help adults manage weight through appetite reduction and support of sustainable, long-term outcomes.

“During a period of significant advancement in obesity care, these studies examine the ways in which treatments such as CONTRAVE may expand current therapeutic options through greater understanding of both behavioral and biological determinants of weight management,” said Michael Kyle, M.D., Chief Medical Officer of Currax Pharmaceuticals. “We continue to support the scientific community in expanding understanding of how evidence-based, accessible options can meet patients where they are on their journey toward improved health.”

ObesityWeek 2025 — Poster presentations included in the press conference

• Fixed-Dose, Extended-Release Combination of Naltrexone and Bupropion Reduces Craving and Body Weight
  Presenter: Dr. Robert F. Kushner, Professor Emeritus of Endocrinology, Metabolism and Molecular Medicine, Northwestern Feinberg School of Medicine
  Date & time: Nov. 4, 2025, 7:30–8:30 p.m.
• Predictors of Response to Fixed-Dose, Extended-Release Combination of Naltrexone and Bupropion
  Presenter: Dr. Donna Ryan, Associate Executive Director for Clinical Research, Pennington Biomedical Research Center
  Date & time: Nov. 4, 2025, 7:30–8:30 p.m.
• Fixed-Dose, Extended-Release Combination of Naltrexone and Bupropion Reduces Body Weight and Smoking
  Presenter: Dr. Christopher Still, Director of Nutrition and Weight Management, Geisinger Medical Center
  Date & time: Nov. 6, 2025, 2:30–3:30 p.m.
• Use of Naltrexone-Bupropion in Persons with Overweight/Obesity and Symptoms of Depression
  Presenter: Dr. Caroline M. Apovian, Co-Director, Center for Weight Management and Wellness, Brigham and Women’s Hospital
  Date & time: Nov. 4, 2025, 7:30–8:30 p.m.

Additional ObesityWeek 2025 presentations

• Weight Loss With Naltrexone-Bupropion Is Associated with Depression and Anxiety in Obesity
  Presenter: Dr. Jose Villamarin, Post-Doctoral Research Fellow, Gastroenterology and Hepatology, Mayo Clinic
  Date & time: Nov. 4, 2025, 1:45–2:00 p.m.; Room A311–A312
• Analyzing Changes in Diet Quality and Caloric Intake for Patients Taking Naltrexone/Bupropion
  Presenter: Dr. Jeffrey Alfonsi, MD, FRCPC, Dipl ABOM & ABLM, Chief Medical Officer of RxFood
  Date & time: Nov. 4, 2025, 7:30–8:30 p.m.
• Potential Obesity Cost Savings Resulting from Naltrexone-Bupropion Treatment: A US Real-World Survey
  Presenter: David Savastano, Ph.D., Senior Director, Medical Affairs, Currax
  Date & time: Nov. 4, 2025, 7:30–8:30 p.m.

About Currax

Currax is a specialty pharmaceutical company that pursues transformative therapies for chronic conditions, including obesity. Combining scientific advancement with patient-centered care, Currax aims to deliver therapies that provide meaningful improvements in health. Currax’s flagship product is CONTRAVE® (naltrexone HCl/bupropion HCl). Learn more at www.curraxpharma.com.

About CONTRAVE

CONTRAVE is an extended-release fixed-dose combination of naltrexone and bupropion indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least one weight-related comorbidity (for example: high blood pressure, high cholesterol, or type 2 diabetes). For full Prescribing Information, including BOXED WARNING and Medication Guide, visit www.contrave.com.

What is CONTRAVE?

CONTRAVE is a prescription weight-loss medicine that may help some adults with a BMI of 30 kg/m2 or greater, or a BMI of 27 kg/m2 or greater with at least one weight-related medical problem, lose weight and keep it off. CONTRAVE should be used with a reduced-calorie diet and increased physical activity.

Important Safety Information (summary)

CONTRAVE can cause serious side effects. Key safety considerations include:

• Suicidal thoughts or actions: One ingredient, bupropion, has been associated with suicidal thoughts or actions and unusual changes in behavior. Monitor closely, especially when starting treatment or changing dose.
• Seizures: CONTRAVE increases the risk of seizures. Do not take other medicines unless your healthcare provider says it is okay. If a seizure occurs, stop CONTRAVE and call your healthcare provider.
• Opioid interactions and withdrawal: Do not take CONTRAVE if you are dependent on opioids or have used opioids in the 7–10 days before starting, as naltrexone can precipitate sudden opioid withdrawal. Do not attempt to overcome naltrexone’s opioid-blocking effects by taking large amounts of opioids, which can cause overdose.
• Severe allergic reactions, liver injury, and increases in blood pressure or heart rate: Seek immediate medical attention for rash, signs of liver problems, or symptoms of cardiovascular issues.
• Manic episodes and psychiatric symptoms: Bupropion can trigger manic episodes in people with a history of bipolar disorder and may worsen depression or cause other behavior changes.
• Other risks: Angle-closure glaucoma and low blood sugar in people with type 2 diabetes taking other glucose-lowering medicines are possible risks.

The most common side effects include nausea, constipation, headache, vomiting, dizziness, trouble sleeping, dry mouth, and diarrhea. This is not a complete list of side effects.

For full prescribing information, including the BOXED WARNING, Medication Guide, contraindications, warnings, and precautions, please see the Full Prescribing Information and Medication Guide.

Please report negative side effects of prescription drugs to the FDA at www.fda.gov/medwatch or by calling 1-800-FDA-1088.

Media contact: [email protected]

Source: Currax Pharmaceuticals LLC